

**MISC. FEE TRANSMITTAL**

Patent fees are subject to annual revision.

DEC 11 2008

TOTAL AMOUNT OF PAYMENT

\$180

**Complete if Known**

Application Number	10/680,963
Filing Date	October 7, 2003
First Named Inventor	Bobrowicz et al.
Examiner Name	C.X. Qian
Group Art Unit	1636
Attorney Docket Number	GF0021YIC

**METHOD OF PAYMENT**☒ Deposit Account

Deposit Account Number 13-2755

Deposit Account Name Merck &amp; Co., Inc.

The Director is authorized to:

☒ Charge fee(s) indicated below☒ Credit any overpayments☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17**FEE CALCULATION****FEES****Large Entity**

Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	
1053	130	Non-English Specification	
1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1402	540	Filing a brief in support of an appeal	
1452	540	Petition to revive - unavoidable	
1453	1,620	Petition to revive - unintentional	
1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	Submission of Information Disclosure Statement	180
1809	810	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	810	For each additional invention to be examined (37 CFR 1.129(b))	
1814	140	Statutory Terminal Disclaimer under 37 CFR 1.321	
Other fee (specify)			
Other fee (specify)			

TOTAL \$180

**SUBMITTED BY****Complete (if applicable)**

Typed or Printed Name

JOHN DAVID REILLY

Reg. Number 43,039

Signature


Date

Dec 9, 2008

Deposit Account User ID

# MISC. FEE TRANSMITTAL

Patent fees are subject to annual revision.



Complete if Known

Application Number	10/680,963
Filing Date	October 7, 2003
First Named Inventor	Bobrowicz et al.
Examiner Name	C.X. Qian
Group Art Unit	1636
Attorney Docket Number	GF0021 YIC

TOTAL AMOUNT OF PAYMENT \$180

## METHOD OF PAYMENT

☒ Deposit Account

Deposit Account Number 13-2755

Deposit Account Name Merck & Co., Inc.

The Director is authorized to:

☒ Charge fee(s) indicated below

☒ Credit any overpayments

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17

## FEE CALCULATION

### FEES

#### Large Entity

Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	
1053	130	Non-English Specification	
1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1402	540	Filing a brief in support of an appeal	
1452	540	Petition to revive - unavoidable	
1453	1,620	Petition to revive - unintentional	
1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	Submission of Information Disclosure Statement	180
1809	810	Filing a submission after final rejection (37 CFR 1.129(b))	
1810	810	For each additional invention to be examined (37 CFR 1.129(b))	
1814	140	Statutory Terminal Disclaimer under 37 CFR 1.321	
Other fee (specify)			
Other fee (specify)			

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By John David Reilly Date 12/9/2008  
MERCK & CO., INC.

TOTAL \$180

## SUBMITTED BY

## Complete (if applicable)

Typed or Printed Name

JOHN DAVID REILLY

Signature

Date


Dec 9, 2008

Reg. Number 43,039

Deposit Account User ID

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: P. Bobrowicz



Serial No. 10/680,963

Filed: October 7, 2003

For: N-ACETYLGLUCOSAMINYLTRANSFERASE III  
EXPRESSION IN LOWER EUKARYOTESArt Unit: 1636Examiner: C.X. QianCommissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

12/11/2008 HGBREH1 00000005 132755 10680963

01 FC:1806 180.00 DA

MERCK &amp; CO., INC.

By 

Date

12/9/2008

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☒ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application: The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By:  JOHN DAVID REILLY

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 43,039

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-6914

Date: Dec 8, 2008